Company News
Clearmind Medicine Stock Up 40% on Trial
Clearmind Medicine shares jumped about 40% after announcing its CMND-100 candidate met primary endpoint in Phase I/IIa trial for Alcohol Use Disorder.
The trial showed a high safety and tolerability p
